Applications of 18F-Fluorodexyglucose Positron Emission Tomography on the Diagnosis and Treatment of Carcinoma of Large Intestine_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

WEN Guanghua , DENG Houfu

Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding author：

Keywords：

Carcinoma of large intestine; Positron emission tomography; 18F-fluorodexyglucose

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To introduce the current study on 18F-fluorodexyglucose positron emission tomography (18F-FDG PET) scanning in diagnosis and treatment of carcinoma of large intestine.
Methods The literatures about 18F-FDG PET scanning in diagnosis and treatment of carcinoma of large intestine in recent years were reviewed.
Results 18F-FDG PET scanning is superior to CT and MRI in identificating carcinoma of large intestine recurrence, metastasis in the early stage after operation and staging carcinoma of large intestine.
Conclusion 18F-FDG PET scanning may be one of the accessory examinations in carcinoma of large intestine and may be helpful for the choice of treatment.

Citation： WEN Guanghua,DENG Houfu. Applications of 18F-Fluorodexyglucose Positron Emission Tomography on the Diagnosis and Treatment of Carcinoma of Large Intestine. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2004, 11(2): 180-181. doi: Copy

1.	Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation [J]. Radiology， 1989; 170(2)∶329.
2.	AbdelNabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings [J]. Radiology, 1998; 206(3)∶755.
3.	Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma [J]. J Nucl Med, 1999; 40(4)∶591.
4.	Zealley IA, Skehan SJ, Rawlinson J, et al. Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG pet [J]. Radiographics, 2001; 21 Spec No∶S55.
5.	Frohlich A, Diederichs CG, Staib L, et al. Detection of liver metastases from pancreatic cancer using FDG PET [J]. J Nucl Med, 1999; 40(2)∶250.
6.	Valk PE, Abella-Columna E, Haseman MK, et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer [J]. Arch Surg, 1999; 134(5)∶503.
7.	Zhuang H, Sinha P, Pourdehnad M, et al. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver [J]. Nucl Med Commun, 2000; 21(9)∶793.
8.	Staib L, Schirrmeister H, Reske SN, et al. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? [J]. Am J Surg, 2000; 180(1)∶1.
9.	Kalff V, Hicks RJ, Ware RE, et al. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study [J]. J Nucl Med, 2002; 43(4)∶492.
10.	Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, et al. Fluorine-18-fluorouracil to predict theraphy response in liver metastases from colorectal carcinoma [J]. J Nucl Med, 1998; 39(7)∶1197.

1. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation [J]. Radiology， 1989; 170(2)∶329.
2. AbdelNabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings [J]. Radiology, 1998; 206(3)∶755.
3. Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma [J]. J Nucl Med, 1999; 40(4)∶591.
4. Zealley IA, Skehan SJ, Rawlinson J, et al. Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG pet [J]. Radiographics, 2001; 21 Spec No∶S55.
5. Frohlich A, Diederichs CG, Staib L, et al. Detection of liver metastases from pancreatic cancer using FDG PET [J]. J Nucl Med, 1999; 40(2)∶250.
6. Valk PE, Abella-Columna E, Haseman MK, et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer [J]. Arch Surg, 1999; 134(5)∶503.
7. Zhuang H, Sinha P, Pourdehnad M, et al. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver [J]. Nucl Med Commun, 2000; 21(9)∶793.
8. Staib L, Schirrmeister H, Reske SN, et al. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? [J]. Am J Surg, 2000; 180(1)∶1.
9. Kalff V, Hicks RJ, Ware RE, et al. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study [J]. J Nucl Med, 2002; 43(4)∶492.
10. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, et al. Fluorine-18-fluorouracil to predict theraphy response in liver metastases from colorectal carcinoma [J]. J Nucl Med, 1998; 39(7)∶1197.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Applications of 18F-Fluorodexyglucose Positron Emission Tomography on the Diagnosis and Treatment of Carcinoma of Large Intestine

Abstract Full text Figures/Tables Video References Cited by

Format

Content